跳至主要内容
临床试验/NCT07608549
NCT07608549尚未招募不适用

A Pilot Study to Determine the Feasibility of Electron FLASH Radiotherapy for Treatment of De-novo Cutaneous Lymphoma

Lesley A. Jarvis0 个研究点目标入组 10 人开始时间: 2029年10月31日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
10

研究概览

简要总结

The primary purpose of this research trial is to study the safety of electron FLASH treatment for cutaneous lymphoma lesions. In addition, investigators will confirm the accuracy of dose and dose rate delivery of electron FLASH therapy using on-patient dosimetry measurements in combination with FAST camera imaging. Researchers will also determine the response rates of cutaneous lymphomas treated with a low radiation dose in a single fraction using electron UHDR treatments, followed by an assessment of radiation related skin toxicity.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Device Feasibility
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histologic proof of cutaneous lymphoma.
  • The cutaneous lymphoma is not planned to be treated with definitive, higher dose radiotherapy therapy.
  • Participant is planned to receive a course of palliative radiation therapy at DHMC for a cutaneous lymphomas lesion located on an extremity (see appendix A) that can be encompassed in a field size no larger than 7.5 cm in diameter.
  • No prior history of radiotherapy to the site of planned treatment.
  • Patient agrees to discontinue topical therapy, including steroid creams or chemotherapy agents, to the index lesion 4 weeks prior to the radiation treatment.
  • Participant must be capable of providing informed consent or has an acceptable surrogate capable of providing consent on behalf of the participant.
  • Adults at least 18 years of age
  • Eastern Cooperative Oncology Group performance status of <
  • Women of childbearing potential (WOCBP): Premenopausal females who had at least one menstrual cycle in the past 12-months and capable to become pregnant, must have a negative serum beta-HCG pregnancy test result within seven days prior to start of treatment.
  • WOCBP who are sexually active must agree at study entry to use adequate methods of contraception during treatment.

排除标准

  • Prior radiotherapy to the site of treatment.
  • Index lesion UHDR treatment field is <5cm from the field edge of a synchronously treated CONV lesion.
  • Patient receiving prescribed hormonal therapies.
  • Patients with known NCI CTCAE V5.0 grade 3 or higher active systemic or cutaneous viral, bacterial, or fungal infection.
  • Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment and/or comply with study protocol.
  • Patients with dementia or altered mental status that would preclude understanding and rendering of informed consent process.

研究者

发起方
Lesley A. Jarvis
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Lesley A. Jarvis

Principle Investigator

Dartmouth-Hitchcock Medical Center

相似试验